Resolving cancer heterogeneity by single cell sequencing

Xu Xun


Deputy Director of BGI



Theodosius Dobzhansky

"Tree" type of thinking of Genomics
They are different, they are also related


Cancer is a game of cell evolution



Mel Greaves & Carlo C. Maley Colonal evolution in cancer (2012) Nature

Single Cell Genomics Analysis


Sequencing the Single Cell Genome by Next Generation Sequencing (NGS)




Single Cell Genomics Single Cell Isolation



• Digest the tissue and randomly select the single cells by the inverted microscope and microcapillary pipetting.



Whole-genome amplification (WGA) based on multiple-displacement amplification with the phi29 enzyme



Our method


PCR based method

Method Evaluation

- Sample set: single cell from the first Asian genome donor (YH); and control form the same tissue.
- Data set: 13X and 18X for two replications

	Single cell 1	Single cell 2	Control
Raw data (Gb)	35.47	47.99	48.72
Average depth	13.32	17.82	18.03
Genome coverage (%)	95.77	94.46	99.91


Method Evaluation



• No obvious genome wide coverage limitation by single cell sequencing

Method Evaluation

• No obvious genome wide coverage limitation; GC content does impact the even distribution of WGA data.




WGA Artifacts Rate Estimate

(Calculated by comparing consensus sequence between YH single cell and YH million cells data)


Sample ID	FDR (False positive mutation) rate		
Single cell 1	7.2E-5		
Single cell 2	8.9E-5		

Note:

- 1. FDR (False discovery rate) = Error SNP # in single cell/confident homo. SNP # in control;
- 2. Here FDR contains WGA error, sequencing error, and mapping error;
- 3. WGA error: E-5 ~E-6 (J. Guillermo Paez, et al. Nucleic Acids Research, 2004, Vol. 32, No. 9 e71)



FN & FDR sites do not show specific base type bias beyond mutations



Pie Chart of Distribution of Biological Categories of Genes (GO) with Amplification Failure

Amplification failure genes do not show preference on different biological processes

Single Cell on Cancer Genomics

Blocks

Samples limitation


• Heterogeneity

• Cancer Progression

Questions

- Where is the solutions for rare and rarity cancer samples?
- How can we differentiate such a mixed tumor tissues?
- What type of the genetic changes is relevant to cancer development?

Cancer is a game of cell evolution




Mel Greaves & Carlo C. Maley Colonal evolution in cancer (2012) Nature



What is the genetic basis of difference in gifted ability to adapt for high altitude?



50 Tibetan Individuals




40 Han Chinese Individuals

What is the genetic basis of difference in gifted ability to adapt for high altitude?

Xin Yi,et al <u>Sequencing of 50 Human Exomes Reveals Adaptation to High Altitude</u>. *Science*. 2010 July; 329(5987): 75-78

• Building phylogenetic tree and structure analysis for different groups of people using




Jun Wang, et al. Nature 2008 Nov 6; 456(7218): 60-5. Li R, et al. Nat Biotechnol. 2009 Dec 7.


A Lesson From


High Altitude Adaption


• SNP information shows that Tibetan and Han Chinese are genetically very similar and the evolution history was revealed as follow:



 Here are the power of Population Branch Statistic (PBS) and Genes with significant PBS selection signals







50 Tibetan Individuals

40 Han Chinese Individuals

The gene (*EPAS1*) showing strongest selection signal (up to 80% frequency change in allele distribution)

Function further validated in


- -Association with blood hemoglobin level
- -Expression level difference in placenta

Apply Population Analysis to Cancer

- Heterogeneous individual population
- Phylogenic structure
- Evolution history inference
- Key genes to hypoxia!



- Heterogeneous cell population
- Cell lineage analysis
- Development history inference
- Key genes to tumor?



Four Cases from 1,000 Single Primary Tumor Cells Sequencing

Cancer type	Sample ID	Single cell number Cancer cell #/control cell #(sequencing available number)	Gender	Description
Essential thrombocytosis (ET)	ET	100/31(53/8)	M	a JAK2-negative patient; published on Cell, 2012
Clear cell renal cell cancer (ccRCC-1)	CCRCC-1	20/6 (20/6)	M	a VHL-wild type patient; large patient cohort also analyzed (Guo et al., 2011); published on <i>Cell</i> , 2012
Bladder transitional cell cancer (BTCC)	ВТСС	59/16 (47/11)	M	a muscle invasive type patient; large patient cohort also analyzed (Gui et al., 2011); submitted on Giga-Science
Colon cancer	Colorectal	106/30 (64/6)	M	large patient cohort also analyzed (unpublished); manuscript in preparation


Four Cases from 1,000 Single Primary Tumor Cells Sequencing

Data Sets

Sample name	Coverage(\pm SEM)	Depth(生 SEM)	Cancer cell #/ normal cells #
ET	$73.86\% \pm 5.08\%$	24.57 ± 2.73	53/8
CCRCC-1	$90.07\% \pm 1.93\%$	32.00 ± 7.06	20/6
ВТСС	85.17% \pm 1.41%	40.23 ± 2.21	47/11
Colorectal	$78.27\% \pm 3.39\%$	15.65 ± 1.05	64/6

Notes: All refer to target region of Agilent. We also sequenced the normal tissue (100X exome) or peripheral blood cells (30X exome), and cancer tissues (100X exome) to make quality control.

Four Cases from 1,000 Single Cancer Cells Sequencing Analysis pipeline




Observe the somatic mutation pattern in single cell level

- > Somatic mutation statistics
- > Derived allelic frequency spectrum of somatic mutations
- Mutation prevalence of single cell level in different cancer
- Somatic mutation types of single cell level in different cancer
- Cancer-mutated genes
- Functional validation

Four Cases from 1,000 Single Primary Tumor Cells Sequencing

Essential Thrombocythemia




Myeloproliferative neoplasm
is a kind of hematopoietic
tumours that originate from
the genetically variations
contained hematopoietic stem
cells or progenitors and lead
to abnormal differentiation
and myelopoiesis

A Wright's stained bone marrow aspirate smear of a JAK2-negative ET patient

Four Cases from 1,000 Single Heterogeneity: Tumor Cells Sequencing

Essential Thrombocythemia




Somatic allele frequency between single cell sequencing and millions of cells shows consistency;

²⁹PCA analysis distinguish cancer and normal cells apparently

Four Cases from 1,000 Single Tumor Cells Sequencing

Heterogeneity:


Renal Cancer (ccRCC-1)



Phylogenetic analysis shows three "cancer" cells present among normal cells, and also showed the homogeneity of renal cancer (no obvious subpopulations were observed)

Four Cases from 1,000 Single Progression: Tumor Cells Sequencing


Essential Thrombocythemia



Comparing the simulation of somatic mutated allele frequency and our data shows the potential monoclonal origin of this kind of disease.

Four Cases from 1,000 Single Tumor Cells Sequencing


Progression:



This indicates that this TCC is very likely to originate from only one ancestral tumour cell with heterozygous mutations


Bladder Cancer (BTCC)

The tumour cells could be classified into 3 identifiable subclones with different genetic mutational signatures with 3 different groups of A genes (A, B, C); N represents normal cells here.



Four Cases from 1,000 Single Tumor Cells Sequencing

Bladder Cancer (BTCC)



The tumour evolution inferred by the heatmap

Four Cases from 1,000 Single Tumor Cells Sequencing


Bladder Cancer (BTCC)



• In Clone B, ATM is specifically mutated and found recurring in 5 other TCC patients in the patient cohort. It is a known tumour suppressor that plays a key role as a cell cycle checkpoint kinase in response to DNA damage and is a regulator of a wide variety of downstream proteins (Rotman and Shiloh 1998; Branzei and Foiani 2008). Defects in this gene could increase mutation rate and genome instability and

5 facilitate tumour progression


Four Cases from 1,000 Single Tumor Cells Sequencing



Clone-C-specific mutated genes COL6A3 and KIAA1958 both recurred in 4 additional patients in the patient cohort.
 COL6A3 is reported to have significant changes in expression level in tumour tissue(Smith, Culhane et al. 2009) and is a subunit of collagen IV, a cancer biomarker(Ohlund, Lundin et al. 2009). The KIAA1958 gene encode a unknown protein.

Four Cases from 1,000 Single Tumor Cells Sequencing

Essential Thrombocythemia




Driver prediction of the non-synonymous somatic mutations: Q-score was calculated according to a modified method by (Youn and Simon 2011). Genes with Q-score more than 1 were identified as key genes.

Four Cases from 1,000 Single Tumor Cells Sequencing

Essential Thrombocythemia

G e n e Name	Mutation Type	Monoclone- origin Gene	Functional Analyses
SESN2	Missense	Yes	SESN2 encoded a member of the sestrin family of SESN1-related proteins and was an antioxidant activated by p53. Mutation in SESN2 may lead to lack of DNA repair and damage prevention
ST13	Nonsense	No	ST13 encodes an Hsc70-interacting protein in controlling the activity of regulatory proteins such as steroid receptors and regulators of proliferation or apoptosis. Mutation in ST13 may contribute to loss the control of apoptosis and lead to abnormal proliferation.
NTRK1	Missense	No	A known oncogene, mutation in NTRK1 may contribute to sustained angiogenesis and cell proliferation
ABCB5	Missense	No	Up-regulation of ABCB5 was responsible for multidrug resistance in several cancers

Key genes with known function and correlation with cancer.



Four Cases from 1,000 Single Tumor Cells Sequencing

1.99%

Renal Cancer (ccRCC-1)

 3.26×10^{-1}

Table 2. Key Genes Identified in This Patient								
		Patient	P Value ^b (Passenger	Mutant Allele Frequency in	Mutant Cell			
Gene Name	Mutations	Prevalence (%) ^a	Probability)	Cancer Tissue	Number	Mountain/Hill ^a		
AHNAK	g.chr11:62042132G > A; p.P5445 > S	5%	9.29×10^{-9}	20%	12	М		
LRRK2	g.chr12:38985956A > G; p.l1294 > V	4%	4.28×10^{-4}	8%	8	Н		
SRGAP3	g.chr3:9041948T > A; p.R535 ^a	2%	2.92×10^{-1}	34%	16	М		

^aPatient prevalence means the mutant genes recurred in the 99 ccRCC patients (including this patient); M/H represents mountain or hill gene.


g.chr17:4976948C > G; p.T72 > R

Thanks to the large Chinese ccRCC patient cohort data, we compare the mutations in this patient and mutations in the large patient cohort, and found these recurrently genes.

USP6

^bSignificance of the observed mutation rate over the expected mutation rate in Guo et al. (2012).


Four Cases from 1,000 Single Tumor Cells Sequencing Renal Cancer (ccRCC-1)



Mutated genes landscape: mountain (tissue common mutation) and hill(cell specific mutation) genes;

Four Cases from 1,000 Single Tumor Cells Sequencing

Colorectal



Thanks to the large colon cancer cohort data, we compare the mutations in this patient and mutations in the large patient cohort, and found recurrent genes which may play important roles in this individual.


Functional analysis

Colorectal



SLC12A5 was upregulated in colon cancer cell lines

Construction of wild-type and mutant *SLC12A5* expression **Functional analysis**vector by site-directed mutagenesis




Colorectal

mRNA & protein expression of *SLC12A5* in colon cancer cells transfected with WT and mutant *SLC12A5*-expressing plasmid

Functional analysis	SW480	SWIII6		
RT-PCR	pCMVb SLC12A5.MT SLC12A5.Muk	pcmyb slc12A5.Mit		
SLC12A5				
eta -actin				
Western blot				
SLC12A5				
GAPDH				

Colorectal

Mutant SLC12A5 promoted colony formation




Colorectal


Four Cases from 1,000 Single Tumor Cells Sequencing

Functional analysis


Mutant SLC12A5 promoted colon cancer cell proliferation



SW480 (Stable transfection)



SWIII6 (Stable transfection)



Functional analysis


Colorectal

• A novel oncogenic mutation in *SLC12A5* with growth-promoting and anti-apoptotic function was identified


Summary

- We successfully infer the intratumoral heterogeneity and progression pattern from both blood tumor and solid tumor by single-cell exome sequencing;
- We identified key mutations and genes using independent methods in an individual tumor;
- Our results indicate the further application of single cell sequencing on cancer personalized medicine and target therapy.


Life is a Game of Cell Evolution



Detection Resolution




- 50% of events resolved to within 10.5kb
- 80% of events resolved to within 40kb



- 42.2% of events overlap known hotspots,
 vs 23.4% overlapping 'coldspots' (p<0.001).
- Cannot reject null hypothesis of uniform hotspot usage across cells.

MEETINGBRIEFS>>


THE BIOLOGY OF GENOMES | 8-12 MAY | COLD SPRING HARBOR, NEW YORK



Single-Cell Sequencing Tackles Basic and Biomedical Questions

eager to lighted cell and ing, The sequen cells: o each sr a blood detecte or abou agrees 1 Recom chromo places v the mos tified co seen th was also some 1: Ster in Palo ing sing lab on a of tiny

- Researchers have long sought a way to determine the amount of recombination that occurs in humans, and they have come up with several indirect ways to measure it in families or in populations.
- single-cell sequencing provides a window on recombination, the process by which matching chromosomes exchange pieces of their DNA during cell division. Recombination helps generate genetic diversity by putting various versions of genes together in new combinations.



Acknowledgement

- R&D center of BGI-Shenzhen: cell isolation, amplification, and analysis;
- BGI-Shenzhen Bioinformatics center: perform the analysis;
- BGI-Shenzhen NGS Platform: sequencing;
- Peking University Shenzhen Hospital and Shenzhen Second People's Hospital for providing the renal cancer and bladder cancer samples;
- Peking University First Hospital for providing the leukemia samples;
- Peking University Cancer Hospital for providing the gastric cancer and colon cancer samples;
- Stanford University School of Medicine Prof. Matthew Scott and his lab: collaborate on Medulloblastoma project



International Conference on Genomics

September 27 – 28, 2012 · Children's Hospital of Philadelphia

Come meet CEOs, directors, and senior executives from BGI, Merck, Pfizer, Sanofi, GSK, BMS, Illumina, Life Technologies, NHGRI, FDA, USDA, Harvard, UC Davis and many more!







Visit www.icgamericas.org

With over 40 renowned speakers, including:



Dr. Huanming Yang Chairman & Professor BGI



Dr. Jun Wang **Executive Director** BGI



Dr. Hakon Hakonarson **CAG Director CHOP**



Dr. Eric D. Green Director NHGRI



Dr. George M. Church **Professor** Harvard Medical School



Dr. Rupert Vessey Senior VP Merck



Dr. Stephanie Chissoe **Acting Head of Genetics** GlaxoSmithKline



Dr. James Watters Head of Applied Genomics Global Director of Sanofi Oncology



Dr. Howard-Yana Shapiro Plant Science **Mars Incorporated**



Gregory T. Lucier CEO **Life Technologies**



Frank Witney President & CEO Affvmetrix



Dr. Howard J. Jacob **HMGC Director Medical College of** Wisconsin



Dr. Gabriel G. Haddad **Pediatrics Dept. Chair UC San Diego**



Dr. Richard W. Michelmore **Director UC Davis Genome Center**



Dr. Joe Grav Director and Chair of **Biomedical Engineering OHSU**



Dr. Andy Shih **VP of Scientific Affairs Autism Speaks**



Dr. Eric Brown Director **Division of Microbiology** FDA



Mr. Yingrui Li **Head of Bioinformatics** BGI

Visit www.icgamericas.org